コンテンツへスキップ
Merck

211A-1

Sigma-Aldrich

TSH

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12352203
NACRES:
NA.41

由来生物

rabbit

品質水準

100
500

結合体

unconjugated

抗体製品の状態

Ig fraction of antiserum

抗体製品タイプ

primary antibodies

クローン

polyclonal

詳細

For In Vitro Diagnostic Use in Select Regions (See Chart)

フォーム

buffered aqueous solution

交差性

human

包装

vial of 0.1 mL concentrate (211A-14)
vial of 0.5 mL concentrate (211A-15)
bottle of 1.0 mL predilute (211A-17)
vial of 1.0 mL concentrate (211A-16)
bottle of 7.0 mL predilute (211A-18)

メーカー/製品名

Cell Marque®

テクニック

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

コントロール

pituitary

輸送温度

wet ice

保管温度

2-8°C

視覚化

cytoplasmic

詳細

Anti-TSH is a useful marker in classification of pituitary tumors and the study of pituitary disease. It reacts with TSH-producing cells (thyrotrophs).

品質


IVD

IVD

IVD

RUO

関連事項

TSH Positive Control Slides, Product No. 211S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

物理的形状

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

調製ノート

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

その他情報

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法的情報

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

適切な製品が見つかりませんか。  

製品選択ツール.をお試しください


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

A Gessl et al.
The Journal of clinical endocrinology and metabolism, 79(4), 1128-1134 (1994-10-01)
The McCune-Albright syndrome (MAS) comprises a triad of physical signs: localized bone lesions termed polyostotic fibrous dysplasia, café-au-lait pigmentation of the skin, and autonomous hyperfunction of multiple endocrine systems, including overproduction of GH and T4. A somatic activating point mutation
J J Kovalic et al.
Journal of neuro-oncology, 16(3), 227-232 (1993-06-01)
There is general agreement that postoperative radiation therapy is beneficial for patients with subtotally resected pituitary adenomas. We have identified 41 such patients treated during a 20-year period who received postoperative irradiation for a pituitary adenoma. The usual dose was
N Sanno et al.
The Journal of clinical endocrinology and metabolism, 80(8), 2518-2522 (1995-08-01)
TSH-secreting pituitary adenomas are rare. The transcriptional expression (messenger ribonucleic acids: mRNAs) of TSH beta, GH, and PRL in five patients with TSH-secreting pituitary adenoma was studied by the in situ hybridization (ISH) method in order to elucidate their multiple
E Batanero et al.
Brain, behavior, and immunity, 6(3), 249-264 (1992-09-01)
We evaluated the presence of anterior pituitary hormones; follicle-stimulating hormone (FSH) and its beta-subunit (beta-FSH), luteinizing hormone (LH) and its beta-subunit (beta-LH), beta-subunit of thyroid-stimulating hormone (beta-TSH), adrenocorticotropic hormone (ACTH), growth hormone (GH), and prolactin (PRL); the placental hormone human
N Kuzuya et al.
The Journal of clinical endocrinology and metabolism, 71(5), 1103-1111 (1990-11-01)
Endocrine and immunohistochemical studies were performed in two cases of TSH-secreting pituitary adenomas. The patients had elevated serum TSH and alpha-subunit concentrations despite high serum thyroid hormone levels. In addition, one patient (no. 1) had elevated serum GH levels with

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)